

21 NCAC 46 .2517 is adopted with changes as published in 40:17 NCR 1351:

21 NCAC 46 .2517 INFLUENZA TEST AND TREAT

In accordance with the protocols issued by the State Health ~~Director and Director, which were~~ adopted by the Medical Board and the Board of Pharmacy pursuant to S.L. 2025-37, s. 5.3.(b), including any amendments adopted by the Medical Board and the Board of Pharmacy, a pharmacist ~~may: may either:~~

(a) Order and perform a ~~CLIA-waved~~ CLIA-waived test for influenza, which is a laboratory test authorized by the Food and Drug Administration and waived under the Clinical Laboratory Improvement Amendments of 1988, influenza and initiate treatment pursuant to the results of the CLIA-waived test; or

(b) Initiate prophylactic treatment for ~~certain~~ high-risk patients who have been exposed to ~~influenza~~. influenza, as set forth in the protocols.

These protocols are available at the Board of Pharmacy's office and on its website (www.ncbop.org/protocols). ~~(www.ncbop.org)~~. The pharmacist shall maintain records of compliance with the protocols for three years, pursuant to Section .2300 of this Chapter. years.

History Note: Authority G.S. 90-85.3(b2); 90-85.3A(e); 90-85.6; 90-85.32; 90-85.36; S.L. 2025-37, s. 5.3; Eff. August 1, 2026.